ライフサイエンスコーパス: CMI

1 CMI analyses showed low levels of spot-forming cells aft

2 CMI assessment shortly after the onset of CMV viremia ma

3 CMI associates with TRR, as well as the EcR-USP receptor

4 CMI continues to be substantially more prevalent among d

5 CMI detection sensitivity and specificity of T1 CMR at 3

6 CMI prevalence was 28.9% among deployed veterans and 15.

7 CMI to a neoantigen was difficult to establish.

8 CMI to HAV was virtually absent.

9 CMI to M. avium reconstitutes rapidly after HAART and ap

10 CMI was measured in 31 patients at multiple time points

11 [CMI], Goleta, CA), an interactive telementoring system i

12 a stronger (P = .02) and broader (P = .013) CMI than patients with the CT genotype with chronically

13 Week 4 CMI was a strong predictor of PFS, even in the presence

14 3,4, 5-trimethoxyphenyl)tetrahydrofuran (40, CMI-392) was selected for further study.

15 deltao/o mice, which are unable to activate CMI against the parasite, suppress P. chabaudi infection

16 CL3L1-CCR5 genotypes associated with altered CMI in healthy subjects were similar to those that influ

17 ically derived from epibatidine, CMI-936 and CMI-1145, displayed reduced analgesic activity in both M

18 nsmurality relative to LGE images in AMI and CMI (P<0.001) at 1.5 T.

19 Resolution of edema between AMI and CMI was examined with T2 maps.

20 cell-mediated mechanism of immunity (AMI and CMI, respectively) or by both mechanisms.

21 Several antibody and CMI cytokine responses were examined for correlates of p

22 Antibody and CMI dose-exposure responses, albeit generally of low mag

23 Anti-PA antibody and CMI responses were detected in 94% and 86% of immunized

24 endently with both neutralizing antibody and CMI responses.

25 We previously designed an antibody- and CMI-inducing adjuvant based on poly(dl-lactic-co-glycoli

26 Since ZMI, DMI and CMI all reduce AS to similar levels, these results sugge

27 ation between IL28B.rs12979860 genotypes and CMI is suggestive of a possible important role of CMI in

28 ior TIV administration decreased humoral and CMI responses to A(H1N1)pdm09 vaccine.

29 pendently of their effects on viral load and CMI.

30 VLP serology and CMI responses may be the future intermediate surrogate b

31 SMI and CMI (compared with no MI) were associated with increased

32 However, SMI and CMI were associated with increased mortality among both

33 The incidence rates of both SMI and CMI were higher in men (5.08 and 7.96 per 1000-person ye

34 ZMI and CMI increased the frequency and decreased the duration o

35 However, since ZMI and CMI, but not DMI, increase synaptic concentrations of se

36 the expression phase of an anticryptococcal CMI response in mice.

37 were immunized to mount an anticryptococcal CMI response, our results indicate that immunization ind

38 nduction of a nonprotective anticryptococcal CMI response results in no significant increases in the

39 protective or nonprotective anticryptococcal CMI responses develop.

40 rotective and nonprotective anticryptococcal CMI responses.

41 n that induces a protective anticryptococcal CMI response and one that induces a nonprotective respon

42 Induction of a protective anticryptococcal CMI response includes increases in dendritic cells (DC)

43 earlier development of the anticryptococcal CMI response than in control mice.

44 design elicited the most robust and balanced CMI response.

45 ign capable of eliciting robust and balanced CMI responses to multiple HIV type 1 (HIV-1)-derived ant

46 V pathogenesis through their effects on both CMI and other viral entry-independent mechanisms.

47 e, CC genotype was associated with a broader CMI compared to CT genotype (P = .028).

48 transcription requires chromatin binding by CMI, methylation of H3K4 by TRR and demethylation of H3K

49 uppression of acute P. chabaudi infection by CMI is gammadelta T cell dependent, is independent of NK

50 the elimination of blood-stage parasites by CMI.

51 not accelerate or modulate the anti-Candida CMI response.

52 Chronic postnatal exposure to clomipramine (CMI), a monoamine uptake inhibitor, results in persisten

53 that inhibiting autophagy with clomipramine (CMI), chloroquine or metformin increased apoptosis and s

54 Seventy participants (28.8%) had cortical CMIs (median, 1; range, 0-43).

55 mulation of local Th1-type anti-cryptococcal CMI responses and the development of protective host imm

56 sed children who are receiving HAART develop CMI and antibody to a recall antigen independent of the

57 3.3%) developed SMI and 386 (4.1%) developed CMI.

58 he results indicate that a broad and durable CMI response to HIV DNA vaccines can be induced in a rel

59 er postnatal treatments (P8-P21) with either CMI or zimelidine (ZMI, a selective serotonin uptake inh

60 gonists chemically derived from epibatidine, CMI-936 and CMI-1145, displayed reduced analgesic activi

61 responsible for the sleep deficits following CMI or ZMI treatment.

62 sion, matched odds ratios (ORs) adjusted for CMI and confounders were estimated.

63 ple, distinct mechanisms are responsible for CMI.

64 immune mice, suggesting a critical role for CMI mechanisms in acquired protection in the CNS.

65 Historically, the treatment for CMI has been surgical revascularization.

66 etween-group difference at any follow-up for CMI (p > or = 0.33) or SSI (p > or = 0.08).

67 e significantly shorter in women with a high CMI (PFS, 2.1 months; OS, 12.3 months) versus a low CMI

68 a subset of sporadic chronic mental illness (CMI), which modestly overexpresses human full-length, no

69 ntify cases of chronic multisymptom illness (CMI) based on the case definition from the Centers for D

70 (Gulf War I), chronic multisymptom illness (CMI) was more common among deployed veterans than among

71 gorous genital mucosal cell-mediated immune (CMI) effectors (e.g., IFN-gamma), the CMI-associated hum

72 infiltration during a cell-mediated immune (CMI) reaction.

73 are potent inducers of cell-mediated immune (CMI) response in mice but elicit poor HIV-specific IFN-g

74 ted persistence of the cell-mediated immune (CMI) response in rhesus macaques for at least 18 months

75 , we have examined the cell-mediated immune (CMI) response throughout the course of infection and com

76 a means of detecting a cell-mediated immune (CMI) response to the antigen.

77 effectiveness of the T-cell-mediated immune (CMI) response to the fungal pathogen.

78 The cell-mediated immune (CMI) response was characterized by significant gamma int

79 ctive vs nonprotective cell-mediated immune (CMI) responses against the fungal pathogen, Cryptococcus

80 Cell-mediated immune (CMI) responses and tumor necrosis factor alpha (TNF-alph

81 y virus (HIV)-specific cell-mediated immune (CMI) responses are critical in the early control and res

82 Cell-mediated immune (CMI) responses defined by delayed-type hypersensitivity

83 Postvaccination cell-mediated immune (CMI) responses have not been compared by use of controll

84 We evaluated cell-mediated immune (CMI) responses in mice given a pulmonary infection with

85 protective humoral and cell-mediated immune (CMI) responses in the genital tract mucosa.

86 Cell-mediated immune (CMI) responses to hepatitis C virus (HCV) antigens in ad

87 Antibody and cell-mediated immune (CMI) responses to protective antigen (PA) and lethal fac

88 s, the role of AS03 on cell-mediated immune (CMI) responses, and vaccine safety.

89 tion of virus-specific cell-mediated immune (CMI) responses.

90 found suppression of cell-mediated immunity (CMI) accompanying measles are unclear.

91 t phase of pulmonary cell-mediated immunity (CMI) against Cryptococcus neoformans.

92 ve a crucial role in cell-mediated immunity (CMI) against P. chabaudi malaria, but delta-chain knocko

93 The importance of cell-mediated immunity (CMI) and CD4(+) T lymphocytes in host resistance against

94 determination, using cell-mediated immunity (CMI) as a "gold standard." VZV EIA had a sensitivity, sp

95 ody and VZV-specific cell-mediated immunity (CMI) at baseline, 8 weeks after each dose, and annually

96 Although cell-mediated immunity (CMI) by CD4 Th1-type cells is considered to be the predo

97 res the induction of cell-mediated immunity (CMI) for host survival.

98 Cell-mediated immunity (CMI) is critically important for protection against Eime

99 s suggest that local cell-mediated immunity (CMI) is more important than systemic CMI for protection

100 Although cell-mediated immunity (CMI) is the predominant host defense mechanism against m

101 Although Th1-type cell-mediated immunity (CMI) is the predominant host defense mechanism against m

102 Cs), suggesting that cell-mediated immunity (CMI) may play a role in viral clearance and protection f

103 ression of cutaneous cell-mediated immunity (CMI) reflected by nickel contact hypersensitivity (CHS).

104 specific humoral and cell-mediated immunity (CMI) to herpes zoster (HZ) and protection against HZ mor

105 IL-12 promotes cell mediated immunity (CMI) to intracellular pathogens by augmenting T-helper t

106 l therapy (HAART) on cell-mediated immunity (CMI) to Mycobacterium avium complex (MAC), we measured i

107 ccine), which boosts cell-mediated immunity (CMI) to VZV and decreases the incidence and severity of

108 Cell-mediated immunity (CMI) to VZV was measured by an interferon-gamma (IFN-gam

109 Evidence of vaginal cell-mediated immunity (CMI) was evaluated for the first time in cervicovaginal

110 Cell-mediated immunity (CMI) was measured shortly after viremia onset and longit

111 ntaneous recovery of cell-mediated immunity (CMI) was not seen for TT.

112 body concentrations, cell-mediated immunity (CMI), and immunoglobulin G (IgG) antibody avidity were a

113 protective role for cell-mediated immunity (CMI), humoral immunity, and innate resistance by neutrop

114 -1) relies mainly on cell-mediated immunity (CMI), the determinants of CMI in humans are poorly under

115 ated immunity and/or cell-mediated immunity (CMI).

116 n the development of cell-mediated immunity (CMI).

117 ), a key mediator of cell-mediated immunity (CMI).

118 ted VZV-specific cellular mediated immunity (CMI).

119 979860 genotypes and cell-mediated immunity (CMI).

120 kers of VZV-specific cell-mediated immunity [CMI], measured by means of ELISPOT analysis) in individu

121 This increase in CMI responses translates to an apparent 50- to 200-fold

122 of the infarcted myocardium was increased in CMI and AMI (P<0.05), and T2 of the infarcted myocardium

123 um was increased in AMI (P<0.001) but not in CMI (P>0.20) at both field strengths.

124 07, respectively), which was not observed in CMI (P=0.49 and P=0.81, respectively) at 3 T.

125 A comorbidity index (CMI) was constructed.

126 d 60 months used the Craniomandibular Index (CMI) and Symptom Severity Index (SSI) for jaw function a

127 A cumulative methylation index (CMI) was generated on the basis of six of the 10 genes t

128 FACS analysis, we characterized the induced CMI response.

129 aracterization of natural or vaccine-induced CMI to rotavirus.

130 sition within chronic myocardial infarction (CMI) influences the electric behavior of the heart.

131 against mucosal Candida albicans infection, CMI against a vaginal C. albicans infection in mice is l

132 ine CCL3L1 and HIV coreceptor CCR5 influence CMI in both healthy and HIV-infected individuals.

133 a patient with chronic mesenteric ischemia (CMI) for chronic loose, frequent, and urgent stools.

134 f patients with chronic mesenteric ischemia (CMI) who were treated with percutaneous stent revascular

135 S, 2.1 months; OS, 12.3 months) versus a low CMI (PFS, 5.8 months; OS, 21.7 months).

136 els, among women with MBC, a high versus low CMI at week 4 was independently associated with worse PF

137 Chiari Type I Malformation (CMI) is characterized by displacement of the cerebellar

138 tant induction of both CD4- and CD8-mediated CMI are consistent with a significant role for type 1 im

139 l sham (C), Sildenafil sham (S), Control MI (CMI) and Sildenafil MI (SMI).

140 ence of MI without clinically documented MI (CMI) after the baseline until ARIC visit 4 (1996-1998).

141 s (acute MI [AMI]) and 4 months (chronic MI [CMI]) after MI.

142 Cortical cerebral microinfarcts (CMIs), a novel MRI marker of cerebral vascular disease,

143 ombination of ENZA and autophagy modulators, CMI or metformin significantly reduced tumor growth when

144 and macrophages, two cell types in a murine CMI reaction.

145 5 of 11 (45.5%) in patients with a negative CMI at onset (P=0.004).

146 A negative CMI was more frequently associated with CT genotype amon

147 ufficient blood plasma samples and 97 had no CMI grading (none, incomplete, or ungradable MRI), leavi

148 Compared with participants with no CMIs, those with CMIs had a significantly higher prevale

149 ), Type 1B (mechano-insensitive nociceptors; CMI; n = 24), Type 2 (cold units; n = 2), Type 3 units (

150 zation during induction of the nonprotective CMI response had little effect on cellular and cytokine

151 two individuals presenting with nonsyndromic CMI with or without syringomyelia.

152 Interestingly, roughly 3-5% of CMI patients are diagnosed with KFS.

153 e cytokine response, and hence the degree of CMI in the host response to infection.

154 ify CCL3L1 and CCR5 as major determinants of CMI and demonstrate that these host factors influence HI

155 mediated immunity (CMI), the determinants of CMI in humans are poorly understood.

156 (24067) into CBA/J mice, the development of CMI was required for leukocyte recruitment into the lung

157 e healthy control group showed no effects of CMI.

158 immunospot (ELISPOT) assay for evaluation of CMI responses to rotavirus using frozen PBMCs obtained f

159 timulation is required for the expression of CMI against the parasite, we compared the time courses o

160 crophages, is critical for the generation of CMI.

161 antigen-processing pathway for induction of CMI and antigen-specific cytotoxic T-lymphocyte response

162 This study demonstrates that the kinetics of CMI responses are different after primary vaccination ve

163 ha was required during the efferent phase of CMI for maximal leukocyte recruitment into the lungs, mo

164 Here we have characterized the potency of CMI responses generated in mice and non-human primates a

165 nt study were to determine the prevalence of CMI among deployed and nondeployed veterans 10 years aft

166 ars; P=0.217), but whites had higher rate of CMI than blacks (5.04 versus 3.24 per 1000-person years;

167 like splenic LDC, are negative regulators of CMI responses.

168 most mucosal Candida infections, the role of CMI against vaginal candidiasis is uncertain, both in hu

169 s suggestive of a possible important role of CMI in favoring hepatitis C virus clearance in CC patien

170 ough much has been learned about the role of CMI in the clearance of C. neoformans from the lungs and

171 ine the location, size, and transmurality of CMI with high diagnostic accuracy.

172 taneous stent placement for the treatment of CMI can be performed with a high procedural success and

173 virus in natural infection and the vigor of CMI is modulated by the relative presence or absence of

174 disease may contribute to the development of CMIs.

175 ients developed VZV-specific antibody and/or CMI 2 months after 2 doses of vaccine, and 83% were resp

176 At baseline, a positive CMI test (interferon-gamma>/=0.2 IU/mL) was present in 2

177 In patients with a positive CMI, the incidence of subsequent spontaneous viral clear

178 Similarly, potent CMI responses were induced by the gag/pol regimen, as me

179 s a potentially modifiable factor to prevent CMI-related brain injury.

180 functions during induction of the protective CMI response by influencing the accumulation of all thre

181 (682 vaccinees and 680 placebo recipients), CMI was measured by VZV responder cell frequency and int

182 us define a novel role for CR3 in regulating CMI functions via IL-12.

183 War cohort, a higher prevalence of reported CMI was noted among deployed compared with nondeployed c

184 The prevalence of self-reported CMI symptoms was compared with that collected in 1997-19

185 mphoproliferative cellular immune responses (CMI) to HPV 16 peptides are not associated with CD4 coun

186 at eliciting cell-mediated immune responses (CMI).

187 Similarly, CMI and avidity analyses showed minimal qualitative impr

188 ith connective tissue disorders (CTDs) since CMI and CTDs frequently co-occur and it has been propose

189 In some CMIs but in none of the CMRs, the supernormal period was

190 capable of eliciting HIV-1 antigen-specific CMI responses in mice.

191 ells (PBMCs) were evaluated for HCV-specific CMI responses by interferon gamma (IFN-gamma) enzyme-lin

192 We investigated HCV-specific CMI responses in seronegative children living with HCV-i

193 inia-nonnaive individuals, vaccinia-specific CMI responses were detected by day 7 after vaccination a

194 assess the time course of vaccinia-specific CMI responses, 20 previously vaccinated and 10 vaccinia-

195 that a residual effect of ZV on VZV-specific CMI persisted for >/= 10 years and was enhanced by the b

196 In most subjects, VZV-specific CMI was increased at 6 weeks postvaccination.

197 th baseline and postvaccination VZV-specific CMI were lower in the older age groups.

198 er baseline and postvaccination VZV-specific CMI.

199 multicomponent vaccine designed to stimulate CMI response against the parasitic cycle of C. immitis.

200 June temperature (r = 0.40) and prior summer CMI (r = 0.40) from 1938 to 2007.

201 robotic arm and Hermes voice command system (CMI).

202 e a lack of demonstrable effects by systemic CMI or PMN against vaginitis and suggest that if local T

203 at deficiencies in Candida-specific systemic CMI account solely for the susceptibility to OPC.

204 study investigated Candida-specific systemic CMI in HIV-positive persons with OPC and/or VVC.

205 munity (CMI) is more important than systemic CMI for protection against vaginitis.

206 B10.D2 CD4 T cells induce a strong Th1/CMI pathway that is characterized by IL-2/IFN-gamma expr

207 These data demonstrate that CMI is sufficient for vaccine protection from intestinal

208 In order to investigate the possibility that CMI and KFS are allelic, GDF3 and GDF6 were sequenced le

209 ently co-occur and it has been proposed that CMI patients with CTDs represent a distinct class of pat

210 Unexpectedly, although the CMI and MLL2 PHDf3 domains could bind histone H3, neithe

211 s were used to test associations between the CMI and progression-free survival (PFS), overall surviva

212 mmune (CMI) effectors (e.g., IFN-gamma), the CMI-associated humoral effector, IgG2a, and to some exte

213 An increase in the CMI from baseline to week 4 was associated with worse PF

214 The added value of the CMI in predicting survival outcomes was evaluated and co

215 ot available for the expression phase of the CMI response.

216 ed extensive replacement fibrosis within the CMI territories.

217 The CMIs showed a greater tendency towards supernormality, w

218 The CMIs were graded according to a previously validated pro

219 These effects have been ascribed to CMI's ability to block neonatal active sleep (AS).

220 significantly upregulated in SMI compared to CMI.

221 igand binding studies indicated that the two CMI compounds, in contrast to oxotremorine, showed >6-fo

222 In contrast, Th1-type CMI is highly effective against an experimental Chlamydi

223 vant system EM014 elicited a potent Th1-type CMI profile and provided significant protection, as meas

224 proach for studying Candida-specific vaginal CMI.

225 VZV CMI responses to HZ were similar in zoster vaccine and p

226 and zoster vaccine generated comparable VZV CMI.

227 zoster vaccine and HZ could be compared, VZV CMI values were similar, but antibody titers were lower.

228 Higher VZV CMI at HZ onset was associated with reduced HZ severity

229 Robust VZV CMI at HZ onset correlated with reduced HZ morbidity, wh

230 VZV-CMI and VZV antibodies were significantly increased in v

231 VZV-CMI correlated with lower HIV load but not with CD4 cell

232 VZV-CMI declines greatly with aging, but can be restored by

233 VZV-CMI did not change over the course of >/=3 years of obse

234 VZV vaccines can boost VZV-CMI.

235 ngs support the hypothesis that boosting VZV-CMI protects older adults against herpes zoster and post

236 the 2 HAART-compliant patients developed VZV-CMI.

237 Depressed patients have diminished VZV-CMI responses to zoster vaccine, and treatment with anti

238 ts who developed HZ during the study had VZV-CMI before developing HZ.

239 for VZV-specific cell-mediated immunity (VZV-CMI) by gamma-interferon ELISPOT and responder cell freq

240 s (VZV)-specific cell-mediated immunity (VZV-CMI) in 56 VZV- and HIV-infected children.

241 er virus (VZV) T-cell-mediated immunity (VZV-CMI) in older persons prevents latent VZV in sensory neu

242 s (VZV)-specific cell-mediated immunity (VZV-CMI).

243 However, the vaccine-induced boost in VZV-CMI (which determines the efficacy of the vaccine) is a

244 accine induced a significant increase in VZV-CMI and VZV antibody.

245 phenotypic and functional differences in VZV-CMI in old and young persons are reviewed, as well as th

246 e magnitude and duration of the boost in VZV-CMI in vaccine recipients and the relationship of this b

247 The vaccine-induced increases in VZV-CMI persisted during the 3 years of follow-up, although

248 Because higher levels of VZV-CMI correlate with lower risk and severity of HZ, untrea

249 pressant medications had lower levels of VZV-CMI following administration of zoster vaccine than nond

250 a peak threefold to fourfold increase of VZV-CMI; the VZV weekly reactivation probability at 5% and V

251 odel that integrates within-host data on VZV-CMI and between-host transmission data to simulate HZ in

252 linical reactivation having no effect on VZV-CMI.

253 ession or other mental illness had their VZV-CMI measured prior to vaccination with zoster vaccine or

254 These findings indicate that a weak CMI response contributes to prolonged PRRSV infection an

255 isorder) and depression were associated with CMI among both deployed and nondeployed veterans.

256 nfectious mononucleosis were associated with CMI among deployed veterans, and migraine headaches and

257 headaches and gastritis were associated with CMI among nondeployed veterans.

258 and identify prewar factors associated with CMI.

259 91, 87, and 91%, respectively, compared with CMI.

260 nly at a 1:2 dilution did not correlate with CMI, but sera reactive at dilutions of > or = 1:8 indire

261 gnant ventricular arrhythmias in humans with CMI is unknown.

262 Patients with CMI (n=94) who underwent late-gadolinium-enhanced cardia

263 se, frequent stools with FI in patients with CMI in this difficult to manage gastrointestinal populat

264 Fifty-nine consecutive patients with CMI underwent stent placement in 79 stenotic (>70%) mese

265 Deployed and nondeployed veterans with CMI had similarly poorer quality-of-life measures and hi

266 nifest cardiac diseases were associated with CMIs on 3-T MRI in patients attending a memory clinic, s

267 .86; 95% CI, 3.03-7.08) were associated with CMIs.

268 nd clinically manifest cardiac diseases with CMIs graded on 3-T MRI in a memory clinic population.

269 , 1.00-4.74) were found in participants with CMIs.

270 d with participants with no CMIs, those with CMIs had a significantly higher prevalence of atrial fib

271 Hypointense cores within CMI on balanced steady-state free precession cardiac mag

272 The use of HIC within CMI on balanced steady-state free precession as a marker

273 d steady-state free precession images within CMI likely result from iron depositions.